Method for preparing 5-hydrazinoisoquinoline by using continuous flow microchannel reactor
By performing diazotization and reduction reaction of 5-aminoisoquinoline in a microchannel reactor, combined with appropriate post-treatment steps, the problem of low product purity in traditional processes is solved, and a high purity and high efficiency 5- Preparation of hydrazine isoquinoline, suitable for industrial applications.
Patent Information
- Application Number
- CN202410685777.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
In the process of preparing 5-hydrazine isoquinoline in the prior art, traditional kettle reactions lead to low product purity and lack of effective post-treatment steps, which affects the quality of the product.
The diazotolysis and reduction reaction of 5-aminoisoquinoline is performed using a continuous flow microchannel reactor. High purity is prepared by controlling the reaction conditions such as molar ratio, flow rate and temperature, combined with acidic conditions and post-treatment steps such as extraction and drying. 5-hydrazine isoquinoline.
The efficient preparation of 5-hydrazine isoquinoline is achieved, with a product purity of more than 97.7%, a high yield, and an industrial operability, which improves the stability and continuity of product quality.
Smart Images

Figure BDA0004866910640000011 
Figure BDA0004866910640000021 
Figure BDA0004866910640000031
Abstract
Description
Technical Field
[0001] The present disclosure relates to a method for preparing 5-hydrazinoisoquinoline using a microchannel reactor. Background Art
[0002] Mucosa-associated-lymphoid-tissue lymphoma-translocation 1 (MALT1) is an important protein molecule in the upstream of the NF-κB signaling pathway. It forms a complex CBM with B-cell chronic lymphocytic leukemia / lymphoma 10 (BCL10) and caspase-recruitment domain (CARD) containing membrane-associated guanylate kinase protein 1 (CARMA1), which transmits the signal of proximal antigen receptor protein to IκB kinase (IKK), thereby activating the NF-κB signaling pathway. Excessive activation of the MALT1-NF-κB signaling pathway is closely related to the occurrence of inflammation and tumors.
[0003] WO2022262855A provides a MALT1 inhibitor, whose chemical name is N-(benzo[c][1,2,5]oxadiazol-5-yl)-1-(1-carbonyl-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide, having a structure shown in Formula II. The entire disclosure refers to WO2022262855A.
[0004]
[0005] 5-Hydrazinoisoquinoline is an important raw material for synthesizing N-(benzo[c][1,2,5]oxadiazole-5-yl)-1-(1-carbonyl-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide. The prior art (WO2022262855A, US20130225580A, US20180009797A) all adopts a traditional kettle reaction to prepare 5-aminoisoquinoline through diazotization and reduction reaction, and most of the processes are not subjected to post-treatment purification, and the purity of the obtained product is low.
[0006] Continuous flow micro-reaction technology refers to the technology of using microreactors (including micro-mixers, micro-heat exchangers, micro-separators, micro-controllers, etc.) to carry out chemical reactions in a continuous flow mode. A microreactor is a chemical process intensification device with a sub-millimeter flow channel size. It has the advantages of high mass and heat transfer efficiency, intrinsic safety, good process repeatability, stable product quality, continuous automated operation and high time and space efficiency. Cheng Dang et al. reviewed the research progress of continuous flow micro-reaction technology in achieving "end-to-end" continuous synthesis and preparation from starting materials to terminal APIs or preparations. Taking ibuprofen as an example, they introduced a six-step continuous flow micro-reaction technology route from acetophenone to ibuprofen tablets, including catalytic hydrogenation, bromination, Grignard reaction, hydrolysis, crystallization and drying, which achieved the efficient preparation of ibuprofen tablets. (Research Progress on the Application of Continuous Flow Micro-reaction Technology in Drug Synthesis [J]. Chemical Industry Progress, 2019, 38(1): 556-575.)
[0007] The present invention discloses a method for preparing 5-hydrazinoisoquinoline by using a novel continuous flow microchannel reactor, and a method for synthesizing N-(benzo[c][1,2,5]oxadiazole-5-yl)-1-(1-carbonyl-1,2-dihydroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide by using the method. The method has strong industrial operability. Summary of the invention
[0008] The present disclosure provides a method for preparing 5-hydrazinoisoquinoline using a continuous flow microchannel reactor, comprising:
[0009] 1) introducing solution A containing 5-aminoisoquinoline and solution B containing sodium nitrite into a microchannel reactor to carry out a diazotization reaction;
[0010] 2) a step of performing a reduction reaction using a solution C containing stannous chloride,
[0011]
[0012] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the molar ratio of 5-aminoisoquinoline to sodium nitrite is selected from 1:0.1 to 1:5.
[0013] In some embodiments, in the method for preparing 5-hydrazinoisoquinoline provided by the present disclosure, the molar ratio of 5-aminoisoquinoline to sodium nitrite is selected from 1:0.5-1:1.5, and can be specifically 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, or a value between any two values.
[0014] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the molar ratio of 5-aminoisoquinoline to stannous chloride is selected from 1:0.1 to 1:5.
[0015] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the molar ratio of 5-aminoisoquinoline to stannous chloride is selected from 1:1.5 to 1:5. Specifically, it can be 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, 1:3, 1:3.1, 1:3.2, 1:3.3, 1:3.4, 1:3.5, 1:3.6, 1:3.7, 1:3.8, 1:3.9, 1:4, 1:4.1, 1:4.2, 1:4.3, 1:4.4, 1:4.5, 1:4.6, 1:4.7, 1:4.8, 1:4.9, 1:5, or a value between any two values.
[0016] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the flow rate of the solution A is 1-200 mL / min.
[0017] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the flow rate of solution A is 10-100 mL / min. Specifically, it can be 10 mL / min, 15 mL / min, 20 mL / min, 25 mL / min, 30 mL / min, 35 mL / min, 40 mL / min, 45 mL / min, 50 mL / min, 55 mL / min, 60 mL / min, 65 mL / min, 70 mL / min, 75 mL / min, 80 mL / min, 85 mL / min, 90 mL / min, 95 mL / min, 100 mL / min, or a value between any two values.
[0018] In some embodiments, in the method for preparing 5-hydrazinoisoquinoline provided by the present disclosure, the flow rate of the solution B is 1-100 mL / min.
[0019] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the flow rate of the solution B is 5-50 mL / min. Specifically, it can be 5 mL / min, 10 mL / min, 15 mL / min, 20 mL / min, 25 mL / min, 30 mL / min, 35 mL / min, 40 mL / min, 45 mL / min, 50 mL / min, or any value between two values.
[0020] In some embodiments, the present disclosure provides a method for preparing 5-hydrazinoisoquinoline, wherein the reaction temperature of step 1 is selected from -10-10°C. Specifically, it can be -10°C, -9°C, -8°C, -7°C, -6°C, -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, or a value between any two values.
[0021] In some embodiments, in the method for preparing 5-hydrazinoisoquinoline provided by the present disclosure, the reaction temperature of step 2 is selected from 5-20° C., specifically 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 11° C., 12° C., 13° C., 14° C., 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., or a value between any two values.
[0022] In some embodiments, in the method for preparing 5-hydrazinoisoquinoline provided by the present disclosure, step 1 and step 2 are performed under acidic conditions, and the reagent providing the acidic conditions is selected from one or more of hydrochloric acid and sulfuric acid.
[0023] Another aspect of the present disclosure provides a method for preparing a compound of formula II or a pharmaceutically acceptable salt thereof, comprising the method for preparing 5-hydrazinoisoquinoline provided previously, further comprising the step of reacting 5-hydrazinoisoquinoline to generate a compound of formula II,
[0024]
[0025] Another aspect of the present disclosure provides a pharmaceutical composition, which contains a therapeutically effective amount of a compound of Formula II prepared according to the above method or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0026] The “reaction temperature of step 1” represents the reaction temperature of solution A and solution B in the continuous flow pipeline, that is, the reaction tube temperature.
[0027] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0028] "Pharmaceutically acceptable salts" refer to salts of the compounds disclosed herein, which are safe and effective when used in mammals and have the desired biological activity, and are selected from but not limited to hydrochlorides and sulfates.
[0029] The purity or content described in the present disclosure is determined by HPLC detection, and the compound characterization data is obtained by analyzing the nuclear magnetic resonance spectrum; the reagents used in the present disclosure can be purchased through commercial channels. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 .Example diagram of continuous flow microchannel reactor reaction. DETAILED DESCRIPTION
[0031] The present disclosure will be explained in more detail below in conjunction with embodiments. The embodiments of the present disclosure are only used to illustrate the technical solutions of the present disclosure, and the essence and scope of the present disclosure are not limited thereto.
[0032] Example 1
[0033] 1) Prepare solution A, solution B and solution C
[0034] Solution A: In a 5.0L beaker, add 2.5L of water, 750mL of concentrated hydrochloric acid, and 500g of 5-aminoisoquinoline in batches to prepare Solution A;
[0035] Solution B: In a 2L beaker, add 1.1L water and 0.25kg sodium nitrite, stir until dissolved to prepare solution B;
[0036] Solution C: Add 263 mL of water, 263 mL of concentrated hydrochloric acid, and 1.3 kg of stannous chloride to a 20 L hot and cold integrated reactor, cool to 0-10 °C, and prepare Solution C.
[0037] 2) Diazotization reaction
[0038] The reaction solution obtained by mixing solutions A and B was added dropwise into a reaction kettle containing solution C through a plunger pump and a continuous flow pipeline (the flow rate of solution A was 40 mL / min, the flow rate of solution B was 10 mL / min, and the temperature of the reaction tube was -5°C). After the reaction was completed, the crude product of 5-hydrazinoisoquinoline was obtained by TLC detection.
[0039] 3) Post-processing
[0040] The crude product liquid was transferred to a 50L reactor, and 10L purified water, 10L 2-methyltetrahydrofuran and 7.5L tetrahydrofuran were added. The pH was adjusted to 13-14 with potassium hydroxide solution, extracted with 2-methyltetrahydrofuran (10L×2), and concentrated by rotary evaporation until there was almost no 2-methyltetrahydrofuran remaining, filtered, and dried to obtain 480.0g of 5-hydrazinoisoquinoline, with a yield of 87.0% and a purity of 97.7%.
[0041] Example 2
[0042] 1) Prepare solution A, solution B and solution C
[0043] Solution A: In a 20L hot and cold integrated reactor, add 12L of water, 3L of concentrated hydrochloric acid, and 2kg of 5-aminoisoquinoline to prepare solution A;
[0044] Solution B: Add 4.4L water and 1kg sodium nitrite to a 20L hot and cold integrated reactor, stir until dissolved, and prepare solution B;
[0045] Solution C: In a 20L hot and cold integrated reactor, add 5.2L water, 5.2L concentrated hydrochloric acid, and 5.2kg stannous chloride, cool to 0-20°C, and prepare Solution C.
[0046] 2) Diazotization reaction
[0047] The reaction solution obtained by mixing solutions A and B was added dropwise into a reaction kettle containing solution C through a plunger pump and a continuous flow pipeline (the flow rate of solution A was 60 mL / min, the flow rate of solution B was 15 mL / min, and the temperature of the reaction tube was -5°C). After the reaction was completed, the crude product of 5-hydrazinoisoquinoline was obtained by TLC detection.
[0048] 3) Post-processing
[0049] The crude product was transferred to a 100L reactor, and 10L of purified water, 10L of 2-methyltetrahydrofuran and 10L of tetrahydrofuran were added. The pH was adjusted to 13-14 with potassium hydroxide solution, extracted with 2-methyltetrahydrofuran (5L×2), and concentrated by rotary evaporation until there was almost no 2-methyltetrahydrofuran left. After suction filtration and vacuum drying, 880.0g of 5-hydrazinoisoquinoline was obtained with a yield of 80.0%.
[0050] Comparative Example 1
[0051] Dissolve 5-aminoisoquinoline (5.1 g, 35.37 mmol) in concentrated hydrochloric acid (50 mL) in a reaction flask, add an aqueous solution (20 mL) of sodium nitrite (3.66 g, 53.06 mmol) at 0°C, react for 30 minutes, add a concentrated hydrochloric acid solution (20 mL) of stannous chloride (19.95 g, 88.43 mmol) dropwise, react at room temperature for 3 hours, adjust the pH to 12-14 with a 20% aqueous sodium hydroxide solution, extract with ethyl acetate (30 mL*3), and concentrate the organic phase under reduced pressure to obtain a crude product (4.66 g, yield 80%, purity 78.9%). The residue is purified by silica gel column chromatography eluting with ethyl acetate to obtain 5-hydrazinoisoquinoline (2.33 g, yield: 40.0%, purity: 86.7%).
Claims
1. A method for preparing 5-hydrazinoisoquinoline, comprising: 1) introducing solution A containing 5-aminoisoquinoline and solution B containing sodium nitrite into a microchannel reactor to carry out a diazotization reaction; 2) a step of performing a reduction reaction using a solution C containing stannous chloride, 2. The method according to claim 1, wherein the molar ratio of 5-aminoisoquinoline to sodium nitrite is selected from 1:0.1-1:5, preferably 1:0.5-1:1.
5.
3. The method according to claim 1, wherein the molar ratio of 5-aminoisoquinoline to stannous chloride is selected from 1:0.1-1:5, preferably 1:1.5-1:
5.
4. The method according to claim 1, wherein the flow rate of solution A is 1-200 mL / min, preferably 10-100 mL / min.
5. The method according to claim 1, wherein the flow rate of solution B is 1-100 mL / min, preferably 5-50 mL / min.
6. The method according to claim 1, wherein the reaction temperature in step 1 is selected from -10 to 10°C.
7. The method according to claim 1, wherein the reaction temperature in step 2 is selected from 5-20°C.
8. A method for preparing a compound of formula II or a pharmaceutically acceptable salt thereof, comprising the method for preparing 5-hydrazinoisoquinoline according to any one of claims 1 to 7,
